



PRESS RELEASE

innate pharma

INNATE PHARMA ANNOUNCES 1.5 MILLION EUROS IN TURNOVER FOR THE FIRST QUARTER OF 2007

Marseilles, May 4, 2007

Innate Pharma S.A. (the "Company"), a biopharmaceutical company developing new drug classes targeting innate immunity, today announced a turnover of 1.5 million euros for the first quarter of 2007, compared to 0.3 million euros for the first quarter of 2006.

The following table compares the turnover for the first quarter of 2006 to 2007:

In thousands of euros	First quarter	
	2006	2007
Revenue from collaboration and licensing agreements	325	1,458
Turnover	325	1,458

The significant change in turnover over the two periods is due to the growth in revenue from collaboration and licensing agreements, explained by payments received from Novo Nordisk A/S under the exclusive collaboration and licensing agreement between the two companies. This agreement sets out the principles for the joint development of new drug candidates targeting NK ("Natural Killer") cells. Executed in March 2006, it follows on from a first exclusive license agreement on the drug candidate IPH 2101 (NN 1975) signed by the companies in 2003. The 2006 agreement broadened the scope of the collaboration into a mutually exclusive partnership on the whole field of NK cells pharmacology, including all possible products and indications. Pharmacology of NK cells is one of Innate Pharma's three product platforms. The other two platforms - T $\gamma\delta$ lymphocytes and TLR ("Toll Like Receptors") - have not yet been partnered out by Innate Pharma.

First quarter 2007 revenue in relation with the collaboration and licensing agreement with Novo Nordisk A/S is broken down as:

- Research and development financing from January to March 2007, and
- 3/36 of the lump sum payment received by Innate Pharma on signing the agreement (this lump sum was fully paid in 2006 but is spread in the accounts over three years, the initial duration of the research and development stage of the agreement).

On signature of the partnership, the two companies had indicated that they were expecting 25.0 million euros in revenue for Innate Pharma over the first three years of the collaboration.

In 2006, Innate Pharma booked 6.1 million euros in turnover in relation to this agreement. In 2007, the Company expects to generate a minimum of 7.0 million euros in turnover from this agreement. Taking this perspective into account as well as the good progress made on the ongoing collaborative work, the objective of 25.0 million euros in revenue for Innate Pharma over the first three years of the collaboration was today confirmed by the Company.

Cash, cash equivalent and current financial instruments amounted to 56.0 million euros as at March 31, 2007.

Turnover for the first quarter of 2007 will be published in the French official bulletin BALO on May 7.



PRESS RELEASE

innate pharma

About Innate Pharma:

Founded in 1999 and funded by reference venture capitalists up to its IPO on Euronext in Paris in 2006, Innate Pharma S.A. (Euronext Paris: FR0010331421 – IPH) is a biopharmaceutical company developing first-in-class* drugs targeting innate immunity.

The pioneering work of Innate Pharma's scientific founders and research groups has led to the development of three product platforms (gamma delta T cells, NK cells and TLR), each directly or indirectly validated in clinical oncology settings.

Besides cancer, Innate Pharma's drug candidates have development potential in the treatment of infectious disease and chronic inflammation. The company's most advanced molecule is in Phase II clinical trials in cancer.

With its strong scientific position in innate immunity pharmacology, its robust intellectual property portfolio and its R&D expertise, Innate Pharma intends to become a leading player in the rapidly growing immunotherapeutics market.

Based in Marseilles, France, Innate Pharma had 74 employees as at March 31, 2007.

Learn more about Innate Pharma at www.innate-pharma.com

Practical Information about Innate Pharma shares:

ISIN code FR0010331421

Ticker code IPH

Disclaimer:

This press release, and the information contained herein, does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for shares in Innate Pharma in any country.

For any additional information, please contact:

Innate Pharma

Stéphane Boissel, EVP and CFO
Tel. : +33 (0)4 96 19 05 58
stephane.boissel@innate-pharma.fr

Alize Public Relations

Caroline Carmagnol
Tel. : +33 (0)6 64 18 99 59
caroline.carmagnol@wanadoo.fr

* with new mechanisms of action.